BECTON DICKINSON & CO
In the published model solve dated 2026-Q2, anchored at $189.52, BECTON DICKINSON & CO (BDX) is priced for +10.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• On 9 February 2026 BD spun its Biosciences and Diagnostic Solutions business into Waters Corporation, taking 4 billion dollars of cash and handing its own holders stock representing 39.2% of the combined company, which leaves behind a narrower business built on medication delivery, medication management and prefillable drug-delivery systems [Source: BD spin-off completion announcement, February 2026]. • The pressure point is coverage rather than growth: trailing operating profit covers interes
Is BDX overvalued? See what's priced in →
1,422 institutional managers reported holding BDX in 13F filings for the quarter ended 2026-03-31. Together they hold about 92% of the company; the top 10 hold 49%. 108 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 7.3M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (3.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BDX has cut its share count 25.7% over the past five years, spending $5.00B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting); the current rate is $4.16 a share annually. Cash returned over the past three years: $3.15B in dividends and $3.75B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at BDX over the trailing three years: 2025: 2 buys totaling $1.36M. 29 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BDX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -2.0% | -3.1% |
| 2023-11-22 | -8.3% | -0.9% |
| 2024-02-02 | -0.7% | +3.8% |
| 2024-05-03 | +0.4% | -3.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BDX's latest 8-K filings: 2026-08-06 (items 2.02, 9.01); 2026-07-22 (items 5.02, 7.01, 9.01); 2026-05-29 (items 7.01); 2026-05-20 (items 1.01, 2.03, 9.01); 2026-05-12 (items 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.